CWP232291

DRUG2 trials

Sponsors

JW Pharmaceutical

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelofibrosis

Phase 1

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

CompletedNCT01398462

JW PharmaceuticalAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome +1

Start: 2011-07-31End: 2015-12-31Updated: 2016-03-08

Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

TerminatedNCT03055286

JW PharmaceuticalAcute Myeloid Leukemia

Start: 2017-02-06End: 2025-08-26Updated: 2025-12-26

Related Papers

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Blood Advances2020-05-1160 citations

Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Journal of Clinical Oncology2015-05-2032 citations